Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Fulcrum Therapeutics (NASDAQ: FULC): Rebuilding Around Pociredir After a Trial Setback

Fulcrum Therapeutics is a Cambridge, Massachusetts clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined diseases. For years its identity centered on losmapimod, an oral candidate for facioscapulohumeral muscular dystrophy (FSHD). That program suffered a decisive setback when its pivotal Phase 3 trial …

Nitish Kishor | 10 September 2026

IDEXX Laboratories (NASDAQ: IDXX): The Veterinary Diagnostics Recurring-Revenue Model

IDEXX Laboratories, based in Maine, is the global leader in veterinary diagnostics and software. Its largest business, the Companion Animal Group, sells in-clinic analyzers and their consumables, rapid SNAP tests and reference-laboratory services, creating a razor-and-blades model in which instrument placements drive years of …

Nitish Kishor | 10 September 2026

cbdMD (NYSE American: YCBD): A Consumer CBD Brand Facing Sector Headwinds

cbdMD, based in Charlotte, North Carolina, markets consumer cannabidiol (CBD) products including tinctures, gummies, capsules and topicals, alongside a pet line under the Paw CBD brand. The company sells through e-commerce and retail channels and has positioned itself around wellness and quality. The most …

Nitish Kishor | 10 September 2026

Allarity Therapeutics (NASDAQ: ALLR): Pairing Stenoparib With a Companion Diagnostic

Allarity Therapeutics is a clinical-stage oncology company built around its Drug Response Predictor (DRP) platform, a genomic tool designed to select patients most likely to benefit from a given therapy. Its lead asset, stenoparib, is an orally available inhibitor being studied in advanced ovarian …

Nitish Kishor | 10 September 2026

Aptevo Therapeutics (NASDAQ: APVO): The Mipletamig Bispecific Antibody Program

Aptevo Therapeutics, based in Seattle, is a clinical-stage biotechnology company developing bispecific antibodies through its ADAPTIR and ADAPTIR-FLEX platforms. Its lead candidate, mipletamig, is a T-cell-engaging bispecific designed to target CD123 in acute myeloid leukemia (AML), and the company has reported early clinical activity …

Nitish Kishor | 10 September 2026

ResMed (NYSE: RMD): The MatrixCare Divestiture and 2030 Strategy

ResMed designs and sells devices and cloud-connected software for sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions, alongside out-of-hospital software businesses. On July 7, 2026, the company announced a definitive agreement to sell MatrixCare, its senior-care electronic-health-record platform, to private-equity firm Frazier …

Nitish Kishor | 10 September 2026

STAAR Surgical (NASDAQ: STAA): Life as an Independent Company After the Rejected Alcon Deal

STAAR Surgical, based in Lake Forest, California, is best known for its EVO Implantable Collamer Lens (ICL), a refractive lens implanted to correct nearsightedness and astigmatism as an alternative to laser vision correction. The defining recent event is regulatory in the corporate sense rather …

Nitish Kishor | 10 September 2026

PMV Pharmaceuticals (NASDAQ: PMVP): Updated Ovarian Cancer Data From PYNNACLE

Princeton, New Jersey-based PMV Pharmaceuticals is a precision oncology company built around p53, one of the most commonly mutated tumor-suppressor genes in cancer. Its lead candidate, rezatapopt (formerly PC14586), is a small molecule designed to reactivate the function of the p53 protein in tumors …

Nitish Kishor | 10 September 2026

Nature's Sunshine Products (NASDAQ: NATR): A Guidance Cut Amid Leadership Changes

Utah-based Nature's Sunshine is a natural health and wellness company that manufactures and sells nutritional supplements and personal-care products, largely through a direct-selling and distributor model across multiple international markets. The most recent major update came on August 6, 2026, when the company reported …

Nitish Kishor | 10 September 2026

bioAffinity Technologies (NASDAQ: BIAF): Regaining Nasdaq Compliance After a Reverse Split

San Antonio, Texas-based bioAffinity Technologies develops non-invasive diagnostics for early-stage lung cancer, led by CyPath Lung, a test that applies flow cytometry to sputum samples to help assess cancer risk. On September 9, 2026, the company said it had regained compliance with Nasdaq's minimum …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…